Scientists test bold new combo against tough blood cancer
NCT ID NCT04161248
Summary
This early study aims to find the safest, highest dose of a new drug when combined with standard lymphoma chemotherapy. It's for adults whose aggressive B-cell lymphoma has returned or hasn't responded to prior treatment. Researchers will carefully increase the dose for small groups of participants to see how much they can tolerate without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BCCA - Vancouver
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-••••
-
Kingston Health Sciences Centre
RECRUITINGKingston, Ontario, K7L 2V7, Canada
Contact Phone: •••-•••-••••
-
The Jewish General Hospital
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-••••
-
University Health Network
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.